Zhejiang Ausun Pharmaceutical Co Ltd
SSE:603229
Zhejiang Ausun Pharmaceutical Co Ltd
SSE:603229
Price:
11.16 CNY
-1.5%
Market Closed
Updated:
May 28, 2024
Section:
Relative Value
The Relative Value of one
Zhejiang Ausun Pharmaceutical Co Ltd
stock under the Base Case scenario is
14.18
CNY.
Compared to the current market price of 11.16 CNY,
Zhejiang Ausun Pharmaceutical Co Ltd
is
Undervalued by 21%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
14.18
CNY
Undervaluation 21%
Valuation Multiples
Multiples Across Competitors
Competitors Multiples
Zhejiang Ausun Pharmaceutical Co Ltd Competitors
Zhejiang Ausun Pharmaceutical Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SSE:603229
|
6.6B CNY | 7.7 | 24.3 | 21.9 | 21.9 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
763.8B USD | 21.2 | 124 | 60.9 | 69.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4.1T DKK | 16.7 | 45.7 | 34.1 | 37.4 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
347.4B USD | 4.1 | 9 | 11.1 | 14.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
319.3B USD | 5.2 | 138.3 | 34.6 | 56.4 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
186.5B GBP | 5 | 37.5 | 174.5 | 278.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
182.4B CHF | 3.1 | 15.9 | 9 | 10.7 | |
| CH |
|
Novartis AG
SIX:NOVN
|
178.3B CHF | 3.3 | 11.1 | 8.5 | 12.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
159.5B USD | 2.9 | -516.2 | 12.6 | 20.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
